Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2024-10-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
天域生物科技股份有限公司拟实施股权收购涉及的天乾食品有限公司股东全部权益价值资产评估报告
Regulatory Filings
2024-10-14 Chinese
关于注销部分已授予但尚未行权的股票期权的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Tianyu Biology Technology Co., Ltd. regarding the cancellation of certain granted but unexercised stock options under the 2022 stock option incentive plan. It details board and supervisory meetings, legal opinions, and the rationale for the cancellation of stock options due to personal changes, expiration of exercise periods, and unmet performance targets. The document is a formal disclosure of a corporate action related to stock options, specifically the cancellation of granted stock options. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a regulatory announcement about a capital change event (cancellation of stock options affects capital structure). Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is under 5,000 characters but contains substantive content about the cancellation, not merely a report publication announcement or certification. Hence, SHA is the correct category with high confidence.
2024-10-14 Chinese
德恒上海律师事务所关于天域生物科技股份有限公司2022年股票期权激励计划首次授予部分第二个行权期及预留授予部分第一个行权期行权条件未成就、注销部分已授予尚未行权的股票期权的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a company's 2022 stock option incentive plan, specifically about the failure to meet certain exercise conditions and the cancellation of unexercised stock options. It details the approval and authorization process, the specific conditions not met, and the resulting cancellation of stock options. The document is not a financial report, earnings release, or management discussion but a legal opinion related to corporate governance and stock option plans. It does not announce a meeting or voting results, nor is it a proxy or remuneration report. It is a specialized legal opinion on stock option incentive plan matters, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a compliance/legal disclosure document.
2024-10-14 Chinese
2024年第五次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled '2024 年第五次临时股东大会会议资料' which translates to '2024 Fifth Extraordinary General Meeting (EGM) Materials'. It contains detailed meeting materials including meeting agenda, voting procedures, and a specific proposal regarding the purchase of minority equity in a subsidiary and related party transactions. The content is focused on the materials prepared for the shareholders to review and discuss at the EGM. There are no financial statements or audit reports presented, nor is this a transcript or announcement of voting results. The document is clearly the meeting materials shared for the shareholders' review before or during the EGM. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary ones).
2024-10-14 Chinese
关于购买控股子公司少数股东股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the purchase of minority equity in a controlled subsidiary by the parent company, involving a related party transaction. It includes extensive information about the transaction terms, parties involved, valuation reports, board and supervisory committee approvals, and the necessity and impact of the transaction. The document is not a financial report, earnings release, or management discussion but rather a formal announcement of a capital transaction involving share acquisition and related party disclosures. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a capital/financing update related to changes in ownership structure and related party transactions. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2024-10-14 Chinese
关于召开2024年第五次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2024 fifth extraordinary general meeting of shareholders (临时股东大会) for Tianyu Bio-Technology Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and procedural instructions for shareholders. There is no financial data, earnings information, or detailed report content. The document is an announcement informing shareholders about the meeting and how to participate, not the actual meeting materials or results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-10-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.